Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant chemo-immunotherapy for stage III PD-L1-positive NSCLC
2024-519205-35-01Phase 2Authorised
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Jul 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of odronextamab, cisplatin, pemetrexed, carboplatin and paclitaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Fondazione Ricerca Traslazionale. Primary endpoint: Complete tumor resection rate (R0). Planned start Jul 2025; status: authorised.
02
Drugs
odronextamabcisplatinpemetrexedcarboplatinpaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-519205-35-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519205-35-01.